Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
DSGN 
Design Therapeutics Inc (DSGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: DSGN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.33
1 Year Target Price $7.33
| 0 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -72.88% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 333.72M USD | Price to earnings Ratio - | 1Y Target Price 7.33 |
Price to earnings Ratio - | 1Y Target Price 7.33 | ||
Volume (30-day avg) 3 | Beta 1.62 | 52 Weeks Range 2.60 - 7.77 | Updated Date 09/16/2025 |
52 Weeks Range 2.60 - 7.77 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.02% | Return on Equity (TTM) -26.77% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 129067199 | Price to Sales(TTM) 22642.01 |
Enterprise Value 129067199 | Price to Sales(TTM) 22642.01 | ||
Enterprise Value to Revenue 11004.35 | Enterprise Value to EBITDA -0.84 | Shares Outstanding 56948100 | Shares Floating 23335064 |
Shares Outstanding 56948100 | Shares Floating 23335064 | ||
Percent Insiders 35.98 | Percent Institutions 63.03 |
Upturn AI SWOT
Design Therapeutics Inc
Company Overview
History and Background
Design Therapeutics Inc. was founded in 2017. The company is a clinical-stage biotechnology company focused on developing disease-modifying therapies for the treatment of serious inherited diseases caused by gene dysfunction.
Core Business Areas
- Discovery Platform: Utilizes a platform to create Gene Targeted Chimeras (GeneTACs), small molecules designed to selectively enhance or suppress gene expression to address the underlying cause of diseases.
- Clinical Development: Focuses on advancing GeneTACs through clinical trials for diseases with limited or no treatment options.
Leadership and Structure
The company's leadership team consists of industry veterans with expertise in drug discovery, development, and commercialization. The organizational structure is typical of a biotechnology company, with departments focused on research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- DT-216: A GeneTAC program targeting Friedreichu2019s Ataxia (FA). Currently in clinical development. Competitors include Retrotope (in acquisition by Chiesi) and Larimar Therapeutics (LRMR). Market share is currently negligible, as no disease-modifying therapies for FA are currently available. Total FA market estimated to be $5-10 Billion
- GeneTACs for DMD: Preclinical GeneTAC programs targeting Duchenne Muscular Dystrophy (DMD). Competitors include Sarepta Therapeutics (SRPT), Solid Biosciences (SLDB) and Vertex (VRTX).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, long development timelines, and regulatory hurdles. There is a high demand for effective treatments for genetic diseases.
Positioning
Design Therapeutics is positioned as an innovator in the field of gene-targeted therapeutics, with a focus on addressing the root causes of genetic diseases. Its GeneTAC platform provides a competitive advantage in developing novel therapies.
Total Addressable Market (TAM)
The TAM for genetic disease treatments is substantial, estimated to be in the tens of billions of dollars, but disease specific. Design Therapeutics is positioned to capture a portion of this market with its targeted approach.
Upturn SWOT Analysis
Strengths
- Novel GeneTAC platform
- Strong scientific team
- Focus on underserved genetic diseases
- Potential for disease-modifying therapies
Weaknesses
- Early stage clinical development
- High cash burn rate
- Dependence on successful clinical trial outcomes
- Limited commercial infrastructure
Opportunities
- Expansion of GeneTAC platform to other genetic diseases
- Partnerships with pharmaceutical companies
- Positive clinical trial data
- Orphan drug designations
Threats
- Clinical trial failures
- Competition from other biotechnology companies
- Regulatory challenges
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- SRPT
- VRTX
- LRMR
- CHMA
Competitive Landscape
Design Therapeutics differentiates itself with its GeneTAC platform. However, it faces competition from larger, more established biotechnology companies with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited, as the company is focused on clinical development.
Future Projections: Future growth is dependent on the success of its clinical programs, estimated by analysts to generate large revenue in the future pending clinical success.
Recent Initiatives: Advancing DT-216 through clinical trials, expanding GeneTAC platform to other diseases.
Summary
Design Therapeutics is a clinical-stage company with a novel platform for addressing genetic diseases, showing potential but facing risks typical of drug development. Success hinges on its clinical trials and ability to secure partnerships. The company has potential for significant growth, but high financial risk associated with biotechnology companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Consider consulting with a financial expert before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Design Therapeutics Inc
Exchange NASDAQ | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 2021-03-26 | Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson Mr. Pratik Shah Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 57 | Website https://www.designtx.com |
Full time employees 57 | Website https://www.designtx.com | ||
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.